Lantheus Holdings (LNTH) Non-Current Assets (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Non-Current Assets came in at $1.4 billion in Q1 2026, up 122.39% year-on-year from $631.4 million in Q1 2025, and up 5.79% on a QoQ basis from $1.3 billion in Q4 2025.
Lantheus Holdings (LNTH) Non-Current Assets (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Non-Current Assets data on file, last reported at $1.4 billion in Q1 2026.
- On a quarterly basis, Non-Current Assets rose 122.39% year-over-year to $1.4 billion in Q1 2026; TTM through Mar 2026 was $5.0 billion, a 81.87% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 103.06% from the prior year.
- Non-Current Assets for Q1 2026 stood at $1.4 billion, up from $1.3 billion in the prior quarter.
- Over the last five years, Non-Current Assets for LNTH reached as high as $1.4 billion in Q1 2026 and fell as low as $565.3 million in Q4 2023.
- Historically, Non-Current Assets has averaged $775.5 million across 5 years, with a median of $643.6 million in 2022.
- Across the five-year window, Non-Current Assets fell 12.17% in 2023 and jumped 122.39% in 2026, its largest moves.
- Year by year, Non-Current Assets stood at $643.6 million in 2022, then declined by 12.17% to $565.3 million in 2023, then increased by 15.63% to $653.7 million in 2024, then jumped by 103.06% to $1.3 billion in 2025, then increased by 5.79% to $1.4 billion in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $1.4 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.4 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 1.40 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.40 Bn |
| Dec 31, 2025 | 1.33 Bn |
| Sep 30, 2025 | 1.35 Bn |
| Jun 30, 2025 | 914.26 Mn |
| Mar 31, 2025 | 631.44 Mn |
| Dec 31, 2024 | 653.71 Mn |
| Sep 30, 2024 | 753.92 Mn |
| Jun 30, 2024 | 708.69 Mn |
| Mar 31, 2024 | 682.53 Mn |
| Dec 31, 2023 | 565.33 Mn |
| Sep 30, 2023 | 573.18 Mn |
| Jun 30, 2023 | 585.50 Mn |
| Mar 31, 2023 | 576.01 Mn |
| Dec 31, 2022 | 643.64 Mn |
| Sep 30, 2022 | 594.04 Mn |
| Jun 30, 2022 | 609.40 Mn |
| Mar 31, 2022 | 608.42 Mn |
| Dec 31, 2021 | 627.99 Mn |
| Sep 30, 2021 | 646.30 Mn |
| Jun 30, 2021 | 671.59 Mn |